AI-Native Precision Oncology
DTS Oncology builds proprietary cancer therapeutics through computation, genomics and translational biology. The technology is the scientific engine; the economic product is a portfolio of ownable oncology assets.
Investment thesis
DTS Oncology is being built as an AI-native precision oncology company supported by the genomic, computational and biotechnology capabilities of DTS Genomics. Every capability exists to serve one output: a therapeutic asset we own.
Therapeutic hypothesis→Biomarker→Validation→Proprietary asset→Partnership
Why now
The failure point in oncology is often not effort, but early programme selection: weak biological rationale, poor patient stratification, insufficient biomarkers and late recognition of translational risk.
From tumour biology to computable signal
Company definition
Operating model
The value chain moves from data-driven biological hypotheses to ownable therapeutic assets with clear partnering optionality. The company is organised around repeatable asset creation, not one-off service revenue.
Platform architecture
Computational breadth with translational discipline. Each layer must support a decision: advance, modify, partner or terminate.
Tumour biology, mutations, expression, resistance and patient stratification.
Hypothesis generation, target prioritisation, mechanism mapping and combinatorial logic.
Assays, biomarkers, biological causality, reproducibility and kill criteria.
IP, development plan, indication strategy and a partner-ready package.
Asset origination
The model is not constrained to de novo discovery. Combining origination, acquisition and repositioning broadens the opportunity universe, shortens timelines in selected programmes and creates multiple paths to value inflection.
Create novel therapeutic hypotheses from computation, genomic insight and tumour biology.
Identify undervalued preclinical or clinical assets with incomplete biomarker logic.
Rescue shelved or failed programmes through better indication, combination or patient selection.
First programme
A confidential discovery programme designed to nominate a proprietary, biomarker-led therapeutic opportunity in pancreatic cancer resistance biology.
Pancreatic ductal adenocarcinoma with KRAS G12D biology and high unmet need.
Resistance and adaptive dependency — not another direct KRAS inhibitor.
Converts a platform thesis into a named, diligence-ready discovery programme.
The target matters specifically in the treatment-adapted tumour state.
The dependency is materially stronger in tumour biology than in normal biology.
Evidence is visible in patient-derived data or clinically credible models.
There is a plausible modality: small molecule, biologic, degrader or combination.
The claim space can support meaningful IP beyond a known literature observation.
Programme hypothesis only. No clinical value is claimed before biological validation.
90-day nomination plan
The first proof point is not a clinical claim. It is a defensible package that proves DTS Oncology can convert a disease map into a ranked therapeutic programme.
Output after 90 days: a named programme with target rationale, biomarker hypothesis, validation protocol, budget, timeline, IP hypothesis and explicit GO/NO‑GO gates.
Defensibility
AI alone is not a moat. Sustainable value comes from proprietary selection logic, validated biological insight, data accumulation, IP discipline and control over assets.
Strict entry and kill criteria.
Validation tied to mechanism.
Each programme improves selection.
Composition, use, biomarker, combination and know-how.
Clear packages for pharma diligence.
Each programme advances only when it meets predefined evidence gates — never when computational promise is mistaken for development readiness.
Business model & capital strategy
Individual assets may follow different economic routes depending on evidence, risk, capital requirements and partner interest.
Upfronts, milestones and royalties for partner-led development.
Risk-sharing with pharma, biotech or specialist investors.
Monetisation at defined value-inflection points.
Selective internal development where the upside/risk balance justifies it.
Governance and de-risking
The investor narrative is supported by controls that prevent overclaiming and protect future diligence. Judgement stays human; the platform only makes the evidence legible.
Independent oncology, translational biology, genomics and clinical-development expertise.
Avoid sunk-cost escalation when the biology does not validate.
Traceability, reproducibility and documented modelling assumptions.
Prior-art review, filing cadence and trade-secret discipline.
Early alignment with development pathways and evidentiary standards.
Positioning discipline: we never claim clinical value before clinical evidence exists.
The opportunity
